



### Stable Plaque



### Ruptured Plaque



**You are invited to attend a Satellite Symposium:**

**Lp-PLA<sub>2</sub>: Risk Marker or Risk Factor?**

Presented by Michelle O'Donoghue, M.D., M.P.H.

**Sunday, June 1, 2014**

**17:00 - 17:45**

**82<sup>nd</sup> EAS Congress**

**Madrid, Spain**

## Lipoprotein-associated Phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>): Risk Marker or Risk Factor?

The session provides an overview of the role inflammation plays in the pathogenesis of atherosclerosis and how Lp-PLA<sub>2</sub> may contribute to cardiovascular events. Epidemiological and genetic data will be presented to support the concept that Lp-PLA<sub>2</sub> is a vascular-specific inflammatory risk factor for the progression of atherosclerotic disease and can be measured with a simple blood test. Further results of the recently published LIPID-Study will be presented showing that the reduction of Lp-PLA<sub>2</sub> with statin therapy, independent of baseline Lp-PLA<sub>2</sub> levels, can help predict the reduction in cardiovascular disease events. The results of the STABILITY trial, a phase III trial of the direct Lp-PLA<sub>2</sub> inhibitor darapladib, will also be reviewed.

Presented by:



**Michelle O'Donoghue, MD MPH**  
Assistant Professor, Harvard Medical School  
TIMI Study Group, Cardiovascular Division  
Brigham and Women's Hospital, Boston, USA

Scan with your smartphone  
QR Code reader for more  
information on this event.



**Sunday, June 1, 2014**  
**17:00 - 17:45**

**82<sup>nd</sup> EAS Congress**  
**Madrid, North Convention Centre**  
**Madrid, Spain**

**Room: Manuel de Oya Hall**

For more information on Lp-PLA<sub>2</sub>,  
please visit diaDexus at stand number 3.

**Sponsored by diaDexus, Inc.**